Folfox+Irinotecan+Chemort In Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2027

Conditions
Gastroesophageal Junction AdenocarcinomaEsophagogastric Cancer
Interventions
DRUG

FOLFOX/ nal-IRI

"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1\) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2\) Oxaliplatin via IV, predetermined dosage per protocol~* 3\) Leucovorin via IV, predetermined dosage per protocol~* 4\) 5-Fluorouracil via IV, predetermined dosage per protocol"

DRUG

Paclitaxel

Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).

DRUG

Carboplatin

Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).

RADIATION

Proton Radiation Therapy

Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks

Trial Locations (3)

02115

RECRUITING

Massachusetts General Hospital, Boston

02215

NOT_YET_RECRUITING

Beth-Israel Deaconess Medical Center, Boston

02462

RECRUITING

Massachusetts General Hospital at Newton Wellesley Hospital, Newton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Massachusetts General Hospital

OTHER